{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:05:00Z","timestamp":1790287500517,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T00:00:00Z","timestamp":1719187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2024,9,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Early phase clinical trials in Oncology represent a subspecialised area where UK patient selection is influenced by access to Experimental Cancer Medicine Centres (ECMCs). Equity of access with respect to social determinants of health (SDoH) were explored for two major ECMCs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort study including all referrals to Newcastle and Manchester ECMCs in 2021 was completed. Consent to screening or pre-screening was stratified against SDoH characteristics, including: Index of Multiple Deprivation (IMD) decile, ethnicity and distance to centre.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>1243 patients were referred for trials. IMD quintile 1 (most deprived) patients had reduced likelihood of referral compared to expected population models (OR, 0.67; 95% CI: 0.55 to 0.80, <jats:italic>p<\/jats:italic>\u2009=\u2009&lt;0.0001). IMD quintile 5 (least deprived) had increased likelihood of referral (OR, 1.46; 95% CI: 1.17 to 1.82, <jats:italic>p<\/jats:italic>\u2009=\u20090.0007). Living beyond median distance from Manchester reduced the likelihood of consenting to trials (OR, 0.72; 95% CI: 0.55 to 0.94, <jats:italic>p<\/jats:italic>\u2009=\u20090.015). Ethnicity data represented a White British propensity.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Inequalities in socioeconomic and geographic factors influence referral and enrolment to early phase clinical trials in Northern England. This has implications for equity of access and generalisability of trial results internationally and warrants further study.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-024-02765-w","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T14:03:09Z","timestamp":1719237789000},"page":"685-691","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Social determinants of health inequalities in early phase clinical trials in Northern England"],"prefix":"10.1038","volume":"131","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6578-0560","authenticated-orcid":false,"given":"S.","family":"Rae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Shaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Hoben","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Oluwashegun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Haris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Oing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. G.","family":"Krebs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F. C.","family":"Thistlethwaite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Carter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2606-1082","authenticated-orcid":false,"given":"N.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Greystoke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. M.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Plummer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,24]]},"reference":[{"key":"2765_CR1","unstructured":"APPG on cancer. Cancer inequalities report - Macmillan Cancer Support. Available at: https:\/\/www.macmillan.org.uk\/documents\/getinvolved\/campaigns\/appg\/britainagainstcancer2009\/cancerinequalitiesreport.pdf (Accessed: 02 September 2023)."},{"key":"2765_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/ecc.12267","volume":"24","author":"CL Saunders","year":"2014","unstructured":"Saunders CL, Abel GA, Lyratzopoulos G. \u2018Inequalities in reported cancer patient experience by socio\u2010demographic characteristic and cancer site: evidence from respondents to the English Cancer Patient Experience Survey\u2019. Eur J Cancer Care. 2014;24:85\u201398. https:\/\/doi.org\/10.1111\/ecc.12267.","journal-title":"Eur J Cancer Care"},{"key":"2765_CR3","unstructured":"What are healthcare inequalities? NHS choices. Available at: https:\/\/www.england.nhs.uk\/about\/equality\/equality-hub\/national-healthcare-inequalities-improvement-programme\/what-are-healthcare-inequalities\/#:~:text=Health%20inequalities%20are%20unfair%20and,that%20is%20available%20to%20them (Accessed: 02 September 2023)."},{"key":"2765_CR4","unstructured":"Not \u2018hard to reach\u2019 \u2013 increasing diversity in research participation (no date) NHS choices. Available at: https:\/\/www.england.nhs.uk\/blog\/not-hard-to-reach-increasing-diversity-in-research-participation\/ (Accessed: 02 September 2023)."},{"key":"2765_CR5","unstructured":"Jenkins H. Health inequalities: \u2018we have a moral duty to reduce them\u2019, Cancer Research UK - Cancer News. 2022. Available at: https:\/\/news.cancerresearchuk.org\/2022\/02\/15\/health-inequalities-we-have-a-moral-duty-to-reduce-them\/ (Accessed: 02 September 2023)."},{"key":"2765_CR6","unstructured":"ECMC. Available at: https:\/\/www.ecmcnetwork.org.uk\/ (Accessed: 02 September 2023)."},{"key":"2765_CR7","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1200\/jco.2012.45.0999","volume":"31","author":"A Mohd Noor","year":"2013","unstructured":"Mohd Noor A, Sarker D, Vizor S, McLennan B, Hunter S, Suder A. et al. \u2018Effect of patient socioeconomic status on access to early-phase cancer trials\u2019. J Clin Oncol. 2013;31:224\u201330. https:\/\/doi.org\/10.1200\/jco.2012.45.0999.","journal-title":"J Clin Oncol"},{"key":"2765_CR8","doi-asserted-by":"publisher","first-page":"2700","DOI":"10.1111\/bcp.15242","volume":"88","author":"AS Gross","year":"2022","unstructured":"Gross AS, Harry AC, Clifton CS, Pasqua OD. \u2018Clinical trial diversity: an opportunity for improved insight into the determinants of variability in drug response\u2019. Br J Clin Pharmacol. 2022;88:2700\u201317. https:\/\/doi.org\/10.1111\/bcp.15242.","journal-title":"Br J Clin Pharmacol"},{"key":"2765_CR9","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1056\/nejmp2215609","volume":"388","author":"AL Schwartz","year":"2023","unstructured":"Schwartz AL, Alsan M, Morris AA, Halpern SD. \u2018Why diverse clinical trial participation matters\u2019. N Engl J Med. 2023;388:1252\u20134. https:\/\/doi.org\/10.1056\/nejmp2215609.","journal-title":"N Engl J Med"},{"key":"2765_CR10","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1093\/annonc\/mds526","volume":"24","author":"G Lyratzopoulos","year":"2013","unstructured":"Lyratzopoulos G, Abel GA, Brown CH, Rous BA, Vernon SA, Roland M, et al. \u2018Socio-demographic inequalities in stage of cancer diagnosis: Evidence from patients with female breast, lung, colon, rectal, prostate, renal, Bladder, melanoma, ovarian and endometrial cancer\u2019. Ann Oncol. 2013;24:843\u201350. https:\/\/doi.org\/10.1093\/annonc\/mds526.","journal-title":"Ann Oncol"},{"key":"2765_CR11","unstructured":"Macmillan Cancer Support and NHS Scotland. 2018. Deprivation and Cancer Survival in Scotland: Technical Report https:\/\/www.macmillan.org.uk\/_images\/ISD%20Macmillan%20Deprivation%20Survival%20Technical%20Report_FINAL_tcm9-308832.pdf"},{"key":"2765_CR12","unstructured":"Health Inequalities: Time to talk. - Macmillan Cancer Support. Available at: https:\/\/www.macmillan.org.uk\/assets\/health-inequalities-paper-april-2019.pdf (Accessed: 02 September 2023)."},{"key":"2765_CR13","unstructured":"Deprivation gradient for cancer mortality (2020) Cancer Research UK. Available at: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/mortality\/deprivation-gradient (Accessed: 08 November 2023)."},{"key":"2765_CR14","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s10552-008-9202-1","volume":"19","author":"N Krieger","year":"2008","unstructured":"Krieger N, Chen JT, Ware JH, Kaddour A. \u2018Race\/ethnicity and breast cancer estrogen receptor status: Impact of class, missing data, and modeling assumptions\u2019. Cancer Causes Control. 2008;19:1305\u201318. https:\/\/doi.org\/10.1007\/s10552-008-9202-1.","journal-title":"Cancer Causes Control"},{"key":"2765_CR15","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1001\/archinte.166.17.1907","volume":"166","author":"JN Cormier","year":"2006","unstructured":"Cormier JN, Xing Y, Ding M, Lee JE, Mansfield PF, Gershenwald JE, et al. \u2018Ethnic differences among patients with cutaneous melanoma\u2019. Arch Intern Med. 2006;166:1907. https:\/\/doi.org\/10.1001\/archinte.166.17.1907.","journal-title":"Arch Intern Med"},{"key":"2765_CR16","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1080\/08989620490891412","volume":"11","author":"PA Rochon","year":"2004","unstructured":"Rochon PA, Mashari A, Cohen A, Misra A, Laxer D, Streiner DL, et al. \u2018The inclusion of minority groups in clinical trials: Problems of under representation and under reporting of Data\u2019. Account Res. 2004;11:215\u201323. https:\/\/doi.org\/10.1080\/08989620490891412.","journal-title":"Account Res"},{"key":"2765_CR17","doi-asserted-by":"publisher","unstructured":"Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, et al. \u2018Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018\u2019, JAMA Oncology. 2019;5. https:\/\/doi.org\/10.1001\/jamaoncol.2019.1870.","DOI":"10.1001\/jamaoncol.2019.1870"},{"key":"2765_CR18","unstructured":"Dahlgren G, Whitehead M. European strategies for tackling social inequalities in health: levelling up, Part 2. Copenhagen: WHO Regional Office for Europe; 2007."},{"key":"2765_CR19","doi-asserted-by":"publisher","unstructured":"Asare M, Flannery M, Kamen C. \u2018Social Determinants of Health: a framework for studying cancer health disparities and minority participation in Research\u2019, Oncol Nursing Forum. 2017;44. https:\/\/doi.org\/10.1188\/17.onf.20-23.","DOI":"10.1188\/17.onf.20-23"},{"key":"2765_CR20","doi-asserted-by":"publisher","first-page":"101610","DOI":"10.1016\/j.esmoop.2023.101610","volume":"8","author":"E Charton","year":"2023","unstructured":"Charton E, Baldini C, Fayet Y, Schultz E, Auroy L, Vallier E, et al. \u2018Inequality factors in access to early-phase clinical trials in oncology in France: Results of the EGALICAN-2 study\u2019. ESMO Open. 2023;8:101610. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101610.","journal-title":"ESMO Open"},{"key":"2765_CR21","unstructured":"Ethnicity-facts-figures.service.gov.uk. 2022. Regional ethnic diversity. [online] Available at: https:\/\/www.ethnicity-facts-figures.service.gov.uk\/uk-population-by-ethnicity\/national-and-regional-populations\/regional-ethnic-diversity\/latest [Accessed 26 September 2022]."},{"key":"2765_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1111\/1753-6405.12762","volume":"42","author":"TI Pathirana","year":"2018","unstructured":"Pathirana TI, Jackson CA. \u2018Socioeconomic status and multimorbidity: a systematic review and meta\u2010analysis\u2019. Aust NZ J Public Health. 2018;42:186\u201394. https:\/\/doi.org\/10.1111\/1753-6405.12762.","journal-title":"Aust NZ J Public Health"},{"key":"2765_CR23","unstructured":"Increasing the diversity of people taking part in research (no date) Health Research Authority. Available at: https:\/\/www.hra.nhs.uk\/planning-and-improving-research\/best-practice\/increasing-diversity-people-taking-part-research\/ (Accessed: 08 November 2023)."},{"key":"2765_CR24","doi-asserted-by":"publisher","unstructured":"Hill J, Montross D, Ivarsson M. \u2018Diversity and inclusion in clinical trials: evolution throughout the development of an mrna COVID-19 vaccine\u2019. Front Public Health. 2023;11. https:\/\/doi.org\/10.3389\/fpubh.2023.1113003.","DOI":"10.3389\/fpubh.2023.1113003"},{"key":"2765_CR25","doi-asserted-by":"publisher","first-page":"100903","DOI":"10.1016\/j.eclinm.2021.100903","volume":"36","author":"M Etti","year":"2021","unstructured":"Etti M, Fofie H, Razai M, Crawshaw A, Hargreaves S, Goldsmith LP. \u2018Ethnic minority and migrant underrepresentation in COVID-19 research: causes and solutions\u2019. EClinicalMedicine. 2021;36:100903. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100903.","journal-title":"EClinicalMedicine"},{"key":"2765_CR26","doi-asserted-by":"publisher","unstructured":"Batra U, Biswas B, Prabhash K, Krishna MV. \u2018Differential clinicopathological features, treatments and outcomes in patients with exon 19 deletion and exon 21 L858R EGFR mutation-positive adenocarcinoma non-small-cell lung cancer\u2019, BMJ Open Respir Res. 2023;10. https:\/\/doi.org\/10.1136\/bmjresp-2022-001492.","DOI":"10.1136\/bmjresp-2022-001492"},{"key":"2765_CR27","unstructured":"2023. https:\/\/digital.nhs.uk\/data-and-information\/publications\/statistical\/cancer-registration-statistics\/england-2019\/there-are-higher-rates-of-cancer-in-the-most-deprived-areas NHS choices. Available at Accessed: 08 November"},{"key":"2765_CR28","unstructured":"Bowel cancer incidence statistics (2022) Cancer Research UK. Available at: https:\/\/www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/bowel-cancer\/incidence#heading-Five (Accessed: 08 November 2023)."},{"key":"2765_CR29","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1200\/JCO.2003.08.010","volume":"21","author":"JH Lewis","year":"2003","unstructured":"Lewis JH, Kilgore ML, Goldman DP, Trimble EL, Kaplan R, Montello MJ, et al. \u2018Participation of patients 65 years of age or older in cancer clinical trials\u2019. J Clin Oncol. 2003;21:1383\u20139.","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02765-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02765-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02765-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:03:55Z","timestamp":1724076235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-024-02765-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,24]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,9,7]]}},"alternative-id":["2765"],"URL":"https:\/\/doi.org\/10.1038\/s41416-024-02765-w","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,24]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All conflicts of interest are declared and do not directly relate to this manuscript. CO is on Pfizer, Advisory Board. MGK has received honoraria from Janssen, Roche; consulting\/advisory board fees from Bayer, Ellipses Pharma, Guardant Health, Janssen, OM Pharma, Roche, Seattle Genetics; speakers fees from AstraZeneca, Janssen, Roche and research funding from Roche and Novartis for his institution. MGK has received travel, accommodation, or expenses from AstraZeneca, BerGenBio, Immutep, Janssen and Roche. FT has research funding from: GSK, Novartis. FT has personal income from advisory board\/consultancy\/honoraria\/DSMB: BMS, GSK, T-Knife Therapeutics, Janssen, Immatics, Ixaka, Scenic Biotech, F-Star, Kite, Leucid, and Guidepoint. LC has had consultancy roles for Athenex, Bicycle Therapeutics and Boehringer Ingelheim. She has received institutional funding from Sierra Oncology, Athenex, Takeda, CellCentric, CytomX Therapeutics, Eli Lilly, Boehringer Ingelheim, Bicycle Therapeutics, Lupin Pharmaceuticals, Repare Therapeutics, ADC Therapeutics, Merck Serono and Kronos Bio. AG has received consultancy and speaker fees from: AstraZeneca, Amgen, Boehringer-Ingelheim, Bristol-Myers Squibb, Janssen\/ J and J, MSD, Novartis, Pfizer, Lilly, Takeda, Guardant and Roche. AG has research funding from AstraZeneca. AG is Clinical Director for Cancer North East England Hull and Yorkshire Genomic Medicine Service. NC has research support to team from: AstraZeneca, Orion, F. Hoffmann-La Roche Ltd, Taiho, GSK, Novartis, Starpharma, Bayer, Eisai, UCB, Redx Pharmaceuticals, Stemline Therapeutics, Boehringer Ingelheim, Merck, AstraZeneca, Cancer Research UK, Orion, LOXO-Oncology. NC has received honoraria \/ travel support from: F. Hoffmann-La Roche Ltd. NC is on the advisory board of: F. Hoffmann-La Roche Ltd (unpaid), CUP Foundation (Jo\u2019s Friends) (unpaid). DG has received research funding from: AstraZeneca and institutional research funding from: MSD, Codiak Biosciences, Starpharma,Faron Pharmaceuticals, Synthon, Janssen, AstraZeneca, Roche, BerGenBio, GSK, Bayer, Bicycle Therapeutics, Carrick, Taiho Pharmaceuticals, CytomX Therapeutics, RedX Pharma PLC, Eisai, Octimet, Orion Pharma, Kinex Pharmaceuticals, Boehringer Ingelheim, BMS, Turning Point Therapeutics, Immutep, Agalimmune, Kymab Ltd.\/Sanofi, Blueprint, Astellas, Cellcentric, UCB, Eli Lilly, Seagen, Repare Therapeutics, Timepoint Therapeutics, Astex, Stemline, Crescendo Biologics Ltd., ADC Therapeutics, Genentech, Avacta Life Sciences Ltd., Nurix Therapeutics, Chugai Pharmaceuticals, Incyte. RP has received honoria for attending advisory boards from Pierre Faber, Bayer, Novartis, BMS, Ellipses, Immunocore, Genmab, Astex Therapeutics, MSD, Nerviano, AmLo, Incyte, Cybrexa Benevolent AI and Sanofi Aventis. RP has received honoraria for working as an IDMC member for Alligator Biosciences, GSK, Onxeo, SOTIO Biotech AG, and AstraZeneca. RP has been paid for delivery of educational talks or chairing educational meetings by AstraZeneca, Novartis, Bayer, MSD and BMS. RP has received funds to support attendance at conferences from MSD and BMS.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was registered at each site respectively as a service evaluation audit. Permission was granted to collect retrospective patient data for this study by the respective Quality Improvement and Clinical Audit Committees (The Newcastle Upon Tyne Hospitals NHS Foundation Trust, audit number: 14040; The Christie NHS Foundation Trust, audit number: 3418).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}